Mitchell Keegan

Mitchell Keegan currently serves as Chief Development Officer at Hillstar Bio since June 2024. Prior to this role, Mitchell held several senior positions at Boston Pharmaceuticals from January 2016 to October 2023, including Senior Vice President of Clinical Development and Head of R&D Strategic Planning, where contributions included leading startup initiatives, gaining a substantial portfolio, and enhancing business development efforts. Previous experience includes high-level positions at Verastem, Curis, and Gloucester Pharmaceuticals, with a focus on clinical and regulatory oversight in oncology programs and successful FDA approval initiatives. Mitchell Keegan earned a Ph.D. in Biochemistry and Molecular Biology from the University of Western Sydney and has conducted research at Australia’s Commonwealth Industrial & Scientific Research Organization.